Results from animal models and clinical samples of HCC demonstrated that the combination of CDC7 inhibitor and mTOR inhibitor could significantly inhibit the progression of HCC, and its antitumor effect was significantly better than that of non-specific multi-target drug Sorafenib (73). The gene discussed is CDC7; the disease is hepatocellular carcinoma.